Skip to Content

Notice

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patents and Patent Applications Concerning Bacterial Superantigen Vaccines

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Department of the Army, DoD.

ACTION:

Notice.

SUMMARY:

In accordance with 37 CFR 404.6 and 404.7, announcement is made Start Printed Page 61262of the availability for licensing of U.S. Patent No. 6,399,332 entitled “Bacterial Superantigen Vaccines,” issued June 4, 2002; U.S. Patent No. 6,713,284 entitled “Bacterial Superantigen Vaccines,” issued March 30, 2004; U.S. Patent Application No. 10/757,687 entitled “Bacterial Superantigen Vaccines,” filed January 29, 2004, which is a divisional of U.S. Patent No. 6,713,284; and U.S. Patent Application No. 10/002,784 entitled “Bacterial Superantigen Vaccines,” filed November 26, 2001, which is a continuation in part of U.S. Patent No. 6,713,284. Foreign rights are also available (PCT/US98/16766 and PCT/US01/46540). The United States Government, as represented by the Secretary of the Army, has rights in this invention.

ADDRESSES:

Commander, U.S. Army Medical Research and Material Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.

Start Signature

Brenda S. Bowen,

Army Federal Register Liaison Officer.

End Signature End Supplemental Information

[FR Doc. 05-21068 Filed 10-20-05; 8:45 am]

BILLING CODE 3710-08-M